VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Decline in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 1,609,597 shares, a decline of 21.0% from the January 29th total of 2,036,211 shares. Based on an average daily volume of 1,300,966 shares, the days-to-cover ratio is presently 1.2 days. Approximately 4.2% of the shares of the company are short sold. Approximately 4.2% of the shares of the company are short sold. Based on an average daily volume of 1,300,966 shares, the days-to-cover ratio is presently 1.2 days.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Finally, Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $0.95.

Institutional Trading of VistaGen Therapeutics

Hedge funds have recently bought and sold shares of the business. AdvisorShares Investments LLC raised its holdings in shares of VistaGen Therapeutics by 1.9% during the 3rd quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock worth $735,000 after acquiring an additional 3,884 shares during the period. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics during the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC acquired a new position in VistaGen Therapeutics in the 3rd quarter valued at about $39,000. Boothbay Fund Management LLC raised its position in shares of VistaGen Therapeutics by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock valued at $699,000 after buying an additional 19,166 shares during the period. Finally, Bank of America Corp DE lifted its holdings in VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Price Performance

Shares of VistaGen Therapeutics stock opened at $0.59 on Monday. The stock has a market capitalization of $23.22 million, a P/E ratio of -0.31 and a beta of 0.29. The business has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $2.64. VistaGen Therapeutics has a 12 month low of $0.43 and a 12 month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.14 million. As a group, research analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.